Bone sialoprotein in serum of patients with malignant bone diseases

Clinical Chemistry

Volumn 43, Issue 1, 1997, Pages 85-91

  Withold, Wolfgang ^a   Armbruster, Franz P ^b   Karmatschek, Markus ^b   Reinauer, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b IMMUNDIAGNOSTIK AG   (Germany)

Author keywords

alkaline phosphatase; bone metastases; calcium; carboxyl terminal propeptide; deoxypyridinoline; menopausal status; multiple myeloma; radioimmunoassay; urine

Indexed keywords

ALKALINE PHOSPHATASE; SIALOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE MATRIX; BONE METABOLISM; BONE METASTASIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; RADIOIMMUNOASSAY;

EID: 0031012236     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.1.85     Document Type: Article

References (27)

1. Young MF, Kerr JM, Ibaraki K, Heegaard AM, Robey PG. Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin Orthop 1992;281:275-94.
2. Masi L, Brandi ML, Robey PG, Crescioli C, Calvo JC, Bernabei P, et al. Biosynthesis of bone sialoprotein by a human osteoclast-like cell line (FLG 29.1). J Bone Miner Res 1995;10:187-96.
3. Hunter GK, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem J 1994;302:175-9.
4. Roach HI. Why does bone matrix contain noncollagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 1994;18:617-28.
5. Sodek J, Kim RH, Ogata Y, Li J, Yamauchi M, Zhang Q, Freedman LP. Regulation of bone sialoprotein gene transcription by steroid hormones. Connect Tissue Res 1995;32:209-17.
6. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AP, et al. Cartilage and bone metabolism in rheumatoid arthritis: differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
7. Saxne T, Zunino L, Heinegard D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum 1995;38:82-90.
8. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54.
9. Withold W, Degenhardt S, Grabensee B, Reinauer H. Comparison between serum levels of bone alkaline phosphatase and the carboxyl-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation. Clin Chim Acta 1995;239:143-51.
10. Helger R, Rindfrey H, Hilgenfeldt J. Eine Methode zur direkten Bestimmung des Creatinins im Serum und Urin ohne Enteiweißung nach einer modifizierten Jaffé-Reaktion. Z Klin Chem Klin Biochem 1974;12:344-9.
11. Szász G. γ-Glutamyl-Transpeptidase. In: Bergmeyer HU, editor. Methoden der enzymatischen Analyse. Weinheim: Verlag Chemie, 1974:757-62.
12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
13. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
14. Chenu C, Delmas PD. Platelets contribute to circulating levels of bone sialoprotein in human. J Bone Miner Res 1992;7:47-54.
15. Bellahcene A, Merville MP, Castronovo VTI. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994;54:2823-6.
16. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 1990;66:167-72.
17. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone lesions. J Clin Oncol 1989;7:1909-14.
18. van Straalen JP, Sanders E, Prummel MF, Sanders GT. Bone alkaline phosphatase as indicator of bone formation. Clin Chim Acta 1991;201:27-33.
19. Goziotis A, Sukhu B, Torontali M, Dowhaniuk M, Tenenbaum HC. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 1995;16:317S-27S.
20. Tsuchimoto M, Azuma Y, Higuchi 0, Sugimoto I, Hirata N, Kiyoki M, Yamamoto I. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 1994;66:25-33.
21. Fleisch H. Bisphosphonates. Pharmacology. Sem Arthritis Rheum 1994;23:261-2.
22. Landman JO, Papapoulos SE. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. Osteoporos Int 1995;5:93-6.
23. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-94.
24. Withold W, Rick W. Evaluation of an immunoradiometric assay for determination of bone alkaline phosphatase mass concentration in human sera. Eur J Clin Chem Clin Biochem 1994;32:91-5.
25. Withold W, Schulte U, Reinauer H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem 1996;42:210-7.
26. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 1993;8:643-8.
27. Garnero GD, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.